Amphastar Pharmaceuticals Inc (NASDAQ: AMPH) has reported E.P.S. of $0.75 for its fourth fiscal quarter (ending December 31) versus $0.70 for the same period a year ago — an increase of 7%. Relative to the consensus estimate of $0.91, this was a shortfall of $-0.16. For the latest four quarters through December 31, E.P.S. were $2.85 compared to $1.88 a year ago — an increase of 52%.
Recent Price Action
Amphastar Pharmaceuticals Inc (NASDAQ: AMPH) stock declined modestly by -1.3% on 2/28/24. The stock closed at $54.74. However, this decline was accompanied by normal trading volume at 83% of normal. Relative to the market the stock has been strong over the last nine months and has risen 4.4% during the last week.
Current PriceTarget Research Rating
AMPH’s future returns on capital are forecasted to be above the cost of capital. Accordingly, the company is expected to continue to be a major Value Builder.
Amphastar Pharmaceuticals has a current Value Trend Rating of C (Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing contradictory signals. Amphastar Pharmaceuticals has a slightly negative Appreciation Score of 36 but a slightly positive Power Rating of 64, producing the Neutral Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment